These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Advances in the treatment of virus diseases. Rubenstein D; Tyrrell DA Practitioner; 1971 Oct; 207(240):510-5. PubMed ID: 4332181 [No Abstract] [Full Text] [Related]
27. [Relationships between structure and activity of anthracycline antibiotics of the rhodomycin group: inhibition kinetics of DNA and RNA viruses of the double- and single-strand types]. Körting HJ; Kissling H; Peters G; Senkpiel K; Fleck WF Pharmazie; 1988 May; 43(5):344-6. PubMed ID: 3051055 [TBL] [Abstract][Full Text] [Related]
28. Inducers of interferon and host resistance. VI. Antiviral efficacy of poly I:C in animal models. Nemes MM; Tytell AA; Lampson GP; Field AK; Hilleman MR Proc Soc Exp Biol Med; 1969 Nov; 132(2):776-83. PubMed ID: 5355140 [No Abstract] [Full Text] [Related]
29. Selective virus inhibitors. De Clercq E Microbiologica; 1990 Apr; 13(2):165-78. PubMed ID: 1693749 [TBL] [Abstract][Full Text] [Related]
32. Antiviral effect of octyl gallate against DNA and RNA viruses. Uozaki M; Yamasaki H; Katsuyama Y; Higuchi M; Higuti T; Koyama AH Antiviral Res; 2007 Feb; 73(2):85-91. PubMed ID: 16950523 [TBL] [Abstract][Full Text] [Related]
33. Rifampicin and viruses. Br Med J; 1969 Jun; 2(5657):588-9. PubMed ID: 5798465 [No Abstract] [Full Text] [Related]
34. Putative antiviral activity in hemolymph from adult Pacific oysters, Crassostrea gigas. Olicard C; Renault T; Torhy C; Benmansour A; Bourgougnon N Antiviral Res; 2005 Jun; 66(2-3):147-52. PubMed ID: 15885817 [TBL] [Abstract][Full Text] [Related]
35. Antiviral drug discovery and development: where chemistry meets with biomedicine. De Clercq E Antiviral Res; 2005 Aug; 67(2):56-75. PubMed ID: 16046240 [TBL] [Abstract][Full Text] [Related]
36. [Antiviral inhibitor induction under the influence of some anti-inflammatory agents]. Saratikov AS; Iavorovskaia VE; Luttseva MA; Prishchep TP Farmakol Toksikol; 1976; 39(2):186-90. PubMed ID: 1278351 [TBL] [Abstract][Full Text] [Related]
37. Perspectives and opportunities for novel antiviral treatments targeting virus fitness. Clementi M Clin Microbiol Infect; 2008 Jul; 14(7):629-31. PubMed ID: 18190573 [TBL] [Abstract][Full Text] [Related]
38. Antimicrobial and cytotoxic arylazoenamines. Part III: antiviral activity of selected classes of arylazoenamines. Tonelli M; Boido V; Canu C; Sparatore A; Sparatore F; Paneni MS; Fermeglia M; Pricl S; La Colla P; Casula L; Ibba C; Collu D; Loddo R Bioorg Med Chem; 2008 Sep; 16(18):8447-65. PubMed ID: 18760610 [TBL] [Abstract][Full Text] [Related]
39. The antiviral activity of dipyridamole. Tonew M; Tonew E; Mentel R Acta Virol; 1977 Mar; 21(2):146-50. PubMed ID: 17283 [TBL] [Abstract][Full Text] [Related]
40. [Effect of some disinfectants on virus activity]. Mazur B; Paciorkiewicz W Med Dosw Mikrobiol; 1974; 26(4):333-7. PubMed ID: 4444374 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]